Table 1.
Summary of results of serial measurements of both plasma and urinary NGAL to predict AKI at different time points
| Number of patients | Threshold values (ng/mL) | Sensitivity (95% CI) | Specificity (95% CI) | NPV | AUROC | |
|---|---|---|---|---|---|---|
| pNGAL at 0h for AKI occurrence at 24, 48 or 72 h |
187 |
400 |
0.6 (0.43-0.74) |
0.85 (0.77-0.91) |
0.86 |
0.7668 |
| pNGAL at 24h for AKI occurrence at 48 or 72 h |
125 |
400 |
0.79 (0.54-0.94) |
0.75 (0.64 -0.81) |
0.93 |
0.8807 |
| pNGAL at 48h for AKI occurrence at 72 h |
77 |
400 |
0.73 (0.30-0.94) |
0.95 (0.84-0.99) |
0.92 |
0.8723 |
| uNGAL at 0h hours for AKI occurrence at 24, 48 or 72 h |
163 |
350 |
0.58 (0.39-0.75) |
0.84 (0.76-0.90) |
0.87 |
0.7914 |
| uNGAL at 24h for AKI occurrence at 48 or 72 h |
118 |
350 |
0.75 (0.48- 0.93) |
0.82 (0.71-0.9) |
0.94 |
0.7768 |
| uNGAL at 48h for AKI occurrence at 48 or 72 h | 68 | 350 | 0.75 (0.35-0.97) | 0.88 (0.72- 0.97) | 0.93 | 0.8220 |
NGAL, neutrophil gelatinase-associated lipocalin; AKI, acute kidney injury; CI, confidence interval; NPV, negative predictive value; AUROC, area under the receiver operator characteristic curve; pNGAL, plasma neutrophil gelatinase-associated lipocalin; uNGAL, urine neutrophil gelatinase-associated lipocalin.